Katherine High, MD, the co-founder, president, and CSO of Spark Therapeutics speaks about the commercial success and renaissance of gene therapy. High is the developer of Luxturna, the first approved gene therapy for a hereditary form of blindness called Leber’s congenital amaurosis . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge